Home Cart Sign in  
Chemical Structure| 956104-40-8 Chemical Structure| 956104-40-8

Structure of Apalutamide
CAS No.: 956104-40-8

Chemical Structure| 956104-40-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ARN-509 can compeitively and selectively inhibit androgen receptor with IC50 value of 16 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Apalutamide

CAS No. :956104-40-8
Formula : C21H15F4N5O2S
M.W : 477.43
SMILES Code : O=C(NC)C1=CC=C(N(C(N(C2=CC(C(F)(F)F)=C(C#N)N=C2)C3=O)=S)C43CCC4)C=C1F
MDL No. :MFCD22380626
InChI Key :HJBWBFZLDZWPHF-UHFFFAOYSA-N
Pubchem ID :24872560

Safety of Apalutamide

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360
Precautionary Statements:P201-P202-P281-P308+P313-P405-P501

Isoform Comparison

Biological Activity

Target
  • Androgen Receptor

    Androgen Receptor, IC50:16 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Calu-3 cells 10, 25 µM 48 hours To evaluate the effect of Apalutamide on SARS-CoV-2 infection, results showed that Apalutamide significantly reduced SARS-CoV-2 infection in Calu-3 cells. PMC9961850
Calu-3 cells 1, 5, 10, 25 µM 72 hours To evaluate the effect of Apalutamide on TMPRSS2 protein levels, results showed a non-significant modulation of TMPRSS2 protein levels after apalutamide treatment. PMC9961850
LNCaP 45.48 µM 8 weeks Establish apalutamide-resistant prostate cancer cell lines and confirm that apalutamide activates the release of calcium ions and endoplasmic reticulum stress to enhance autophagy. PMC11155045
C4-2 20.16 µM 8 weeks Establish apalutamide-resistant prostate cancer cell lines and confirm that apalutamide activates the release of calcium ions and endoplasmic reticulum stress to enhance autophagy. PMC11155045

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03365297 Prostate Cancer PHASE2 COMPLETED 2019-07-25 Cambridge University Hospitals... More >> NHS Foundation Trust/Addenbrookes Hospital, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom Less <<
NCT03802682 Healthy PHASE1 COMPLETED 2019-04-11 Clinical Pharmacology Unit, Me... More >>rksem, 2170, Belgium Less <<
NCT03088124 Low Risk Prostate Cancer PHASE2 UNKNOWN 2022-04-28 Institut Paoli Calmettes, Mars... More >>eille, Bouches Du Rh?ne, 13009, France|CHRU Hopital Edouard Herriot, Lyon, 69437, France|Clinique Beau Soleil, Montpellier, 34070, France|Chu Hotel Dieu, Nantes, France|Chu de Nice, Nice, France|Institut Mutualiste Montsouris, Paris, 75014, France|Chu Tenon, Paris, France|Clinique La Croix Du Sud, Quint-Fonsegrives, France|Chu Pontchaillou, Rennes, France|Chu Saint Etienne, Saint Etienne, 42055, France|Hia Sainte Anne, Toulon, France Less <<
NCT03523442 Prostatic Neoplasms PHASE1 ACTIVE_NOT_RECRUITING 2025-12-31 Peking University Third Hospit... More >>al, Beijing, 100083, China|Beijing Cancer Hospital of Peking University, Beijing, 100142, China|Jiangsu Cancer Hospital, NanJing, 210000, China|Fudan Cancer Hospital, ShangHai, 200032, China Less <<
NCT02578797 Castration-Resistant Prostate ... More >>Cancer Less << PHASE1 COMPLETED 2022-10-13 Greenville, South Carolina, Un... More >>ited States|Montreal, Quebec, Canada|Chisinau, Moldova, Republic of|Rotterdam, Netherlands|Sutton, United Kingdom Less <<
NCT04154774 Hepatic Impairment PHASE1 RECRUITING 2025-03-05 Homestead Associates in Resear... More >>ch Inc, Homestead, Florida, 33033, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Genesis Clinical Research, Tampa, Florida, 33603, United States|VGR & NOCCR - Knoxville, Knoxville, Tennessee, 37920, United States Less <<
NCT04997252 High-Risk and Oligometastatic ... More >>Prostate Cancer Less << RECRUITING 2025-12-24 zhujiang Hospital of Southern ... More >>Medical University, Guangzhou, Guangdong, 510200, China Less <<
NCT03124433 Cancer of the Prostate PHASE2 COMPLETED 2019-08-22 Department of Urology, Singapo... More >>re, 169608, Singapore Less <<
NCT04601441 Metastatic Castration-sensitiv... More >>e Prostate Cancer Less << PHASE4 RECRUITING 2025-03-31 Kindai University Hospital, ōs... More >>aka-sayama, Osaka, 589-851, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.47mL

2.09mL

1.05mL

20.95mL

4.19mL

2.09mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Clegg NJ, Wongvipat J, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503.

[2]Hallur G, Purra BR, et al. Validation of an LC-ESI-MS/MS method for the determination of apalutamide, a novel non-steroidal anti-androgen in mice plasma and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2018 May 10;153:260-266.

[3]Saini NK, Sulochana SP, et al. A novel dried blood spot LC-MS/MS method for the quantification of apalutamide in mouse whole blood: Application to pharmacokinetic study in mice. Biomed Chromatogr. 2018 Nov;32(11):e4344.

[4]Pang X, Wang Y, et al. Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2803-2806.

[5]Shukla GC, Plaga AR, Shankar E, Gupta S. Androgen receptor-related diseases: what do we know? Andrology. 2016 May;4(3):366-81. doi: 10.1111/andr.12167. Epub 2016 Mar 16. PMID: 26991422.

[6]Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. PMID: 22266222; PMCID: PMC3306502.

 

Historical Records

Categories